Kynurenine: Difference between revisions
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Notjusttired (talk | contribs) (add image, remove stub) |
Notjusttired (talk | contribs) m (→ME/CFS: improve headings) |
||
| Line 8: | Line 8: | ||
In May 2020, the Open Medicine Foundation announced a pilot treatment trial of kynurenine for [[ME/CFS]].<ref name="maymomentum">{{Cite web|url=https://www.omf.ngo/maymomentum/|title=#May Momentum 2020|last=Open Medicine Foundation|first=|authorlink=Open Medicine Foundation|last2=|first2=|authorlink2=|date=|website=Open Medicine Foundation|language=en-US|archive-url=|archive-date=|dead-url=|access-date=2020-05-01}}</ref> Dr [[Jonas Bergquist]] will be running the trial.<ref name=":0">{{Cite web|url=https://www.omf.ngo/2020/04/26/kynurenine-clinical-trial-for-me-cfs/|title=Kynurenine Clinical Trial for ME / CFS|last=Open Medicine Foundation|first=|authorlink=Open Medicine Foundation|last2=|first2=|authorlink2=|date=2020-04-26|website=Open Medicine Foundation|language=en-US|archive-url=|archive-date=|dead-url=|access-date=2020-05-05}}</ref> | In May 2020, the Open Medicine Foundation announced a pilot treatment trial of kynurenine for [[ME/CFS]].<ref name="maymomentum">{{Cite web|url=https://www.omf.ngo/maymomentum/|title=#May Momentum 2020|last=Open Medicine Foundation|first=|authorlink=Open Medicine Foundation|last2=|first2=|authorlink2=|date=|website=Open Medicine Foundation|language=en-US|archive-url=|archive-date=|dead-url=|access-date=2020-05-01}}</ref> Dr [[Jonas Bergquist]] will be running the trial.<ref name=":0">{{Cite web|url=https://www.omf.ngo/2020/04/26/kynurenine-clinical-trial-for-me-cfs/|title=Kynurenine Clinical Trial for ME / CFS|last=Open Medicine Foundation|first=|authorlink=Open Medicine Foundation|last2=|first2=|authorlink2=|date=2020-04-26|website=Open Medicine Foundation|language=en-US|archive-url=|archive-date=|dead-url=|access-date=2020-05-05}}</ref> | ||
==== Trial type | ==== Trial type ==== | ||
Pilot trial, with cross-over at 3 months. Patients receiving the kynurenine will change to the placebo after 3 months, and patients receiving the placebo will switch to the kynurenine. No control group.<ref name="maymomentum" /><ref name=":0" /> | Pilot trial, with cross-over at 3 months. Patients receiving the kynurenine will change to the placebo after 3 months, and patients receiving the placebo will switch to the kynurenine. No control group.<ref name="maymomentum" /><ref name=":0" /> | ||
==== Aims | ==== Aims==== | ||
To see whether kynurenine improves [[Cognitive dysfunction|cognitive impairment]] (brain fog), [[Headache|headaches]] and [[Memory problems|memory]] in ME/CFS patients.<ref name=":0" /> | To see whether kynurenine improves [[Cognitive dysfunction|cognitive impairment]] (brain fog), [[Headache|headaches]] and [[Memory problems|memory]] in ME/CFS patients.<ref name=":0" /> | ||
==== Patients | ==== Patients ==== | ||
Only 20 out of a group of 100 ME/CFS patients. Patients will be those identified as having a low level of kynurenine in blood serum and ME/CFS.<ref name=":0" /> | Only 20 out of a group of 100 ME/CFS patients. Patients will be those identified as having a low level of kynurenine in blood serum and ME/CFS.<ref name=":0" /> | ||
==== Outcomes | ==== Outcomes ==== | ||
Measurements will be taken from wearable sensors.<ref name=":0" /> | Measurements will be taken from wearable sensors.<ref name=":0" /> | ||
==Learn more== | ==Learn more== | ||
Revision as of 12:27, July 3, 2020
Kynurenine is an amino acid that is produced in the body by the metabolism of the essential amino acid tryptophan.[1][2]
ME/CFS[edit | edit source]
The Open Medicine Foundation's ME/CFS Severely Ill, Big Data Study found that patients in the study group with severe ME had one of several defects involving the IDO2 gene, which affected tryptophan - kynurenine metabolism.[3] This lead to the Metabolic Trap theory.[3]
Uppsala trial, Sweden[edit | edit source]
In May 2020, the Open Medicine Foundation announced a pilot treatment trial of kynurenine for ME/CFS.[4] Dr Jonas Bergquist will be running the trial.[5]
Trial type[edit | edit source]
Pilot trial, with cross-over at 3 months. Patients receiving the kynurenine will change to the placebo after 3 months, and patients receiving the placebo will switch to the kynurenine. No control group.[4][5]
Aims[edit | edit source]
To see whether kynurenine improves cognitive impairment (brain fog), headaches and memory in ME/CFS patients.[5]
Patients[edit | edit source]
Only 20 out of a group of 100 ME/CFS patients. Patients will be those identified as having a low level of kynurenine in blood serum and ME/CFS.[5]
Outcomes[edit | edit source]
Measurements will be taken from wearable sensors.[5]
Learn more[edit | edit source]
- Kynurenine - PubChem
- L-Kynurenine - PubChem
- Kynurenine clinical trial - Open Medicine Foundation
See also[edit | edit source]
References[edit | edit source]
- ↑ "Medical Definition of KYNURENINE". www.merriam-webster.com. Retrieved November 30, 2019.
- ↑ National Center for Biotechnology Information. "Kynurenine". PubChem Database. Retrieved January 19, 2020. Cite has empty unknown parameter:
|dead-url=(help) - ↑ 3.0 3.1 Phair, Robert D.; Davis, Ronald W.; Kashi, Alex A. (2019). "The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS". Diagnostics. 9 (3): 82. doi:10.3390/diagnostics9030082.
- ↑ 4.0 4.1 Open Medicine Foundation. "#May Momentum 2020". Open Medicine Foundation. Retrieved May 1, 2020. Cite has empty unknown parameter:
|dead-url=(help) - ↑ 5.0 5.1 5.2 5.3 5.4 Open Medicine Foundation (April 26, 2020). "Kynurenine Clinical Trial for ME / CFS". Open Medicine Foundation. Retrieved May 5, 2020. Cite has empty unknown parameter:
|dead-url=(help)
